Abstract
Although evidence over the last 30 years suggests that the autonomic nervous system (ANS) mediates stress-induced allostatic and immune responses, the crucial role that it plays in the tumor micro-environment has only recently been reported. Here, we review the action of ANS signaling in this micro-environment. Emerging data suggest that primary tumors are innervated by the ANS which mediates stress-related effects on tumor progression. The activation of the sympathetic nervous system (SNS) takes advantage of neurotransmitters and neuropeptides from the innervating neural circuitry and/or hypothalamic-pituitary-adrenal axis glucocorticoids via their receptors to modulate the gene expression associated with oncogenesis, the proliferation and apoptosis of tumor cells, angiogenesis, and the tumor-associated immune response. The parasympathetic nervous system has also been implicated in some tumor types, but its contribution in the tumor micro-environment remains unclear. In addition to identifying the ANS signaling pathways involved in tumor progression, recent reports suggest that the ANS could be a potential biomarker to predict tumor progression, and have identified new pharmacological strategies, such as the use of β-adrenergic blockers, to inhibit tumor progression and metastasis by targeting this system. These findings are reviewed here.
Keywords: Autonomic nervous system, tumor microenvironment, immune response, sympathetic nervous system, adrenergic signaling.
Current Pharmaceutical Design
Title:Role of the Autonomic Nervous System in the Tumor Micro-Environment and its Therapeutic Potential
Volume: 23 Issue: 11
Author(s): Zhifang Xu, Seiji Shioda, Jinushi Masahisa, Yutaka Kawakami, Hirokazu Ohtaki, Huimin Calista Lim, Shenjun Wang, Xue Zhao, Yangyang Liu, Dan Zhou and Yi Guo*
Affiliation:
- Acu-moxibustion and Tuina Department, Tianjin University of Traditional Chinese Medicine, Tianjin 300193,China
Keywords: Autonomic nervous system, tumor microenvironment, immune response, sympathetic nervous system, adrenergic signaling.
Abstract: Although evidence over the last 30 years suggests that the autonomic nervous system (ANS) mediates stress-induced allostatic and immune responses, the crucial role that it plays in the tumor micro-environment has only recently been reported. Here, we review the action of ANS signaling in this micro-environment. Emerging data suggest that primary tumors are innervated by the ANS which mediates stress-related effects on tumor progression. The activation of the sympathetic nervous system (SNS) takes advantage of neurotransmitters and neuropeptides from the innervating neural circuitry and/or hypothalamic-pituitary-adrenal axis glucocorticoids via their receptors to modulate the gene expression associated with oncogenesis, the proliferation and apoptosis of tumor cells, angiogenesis, and the tumor-associated immune response. The parasympathetic nervous system has also been implicated in some tumor types, but its contribution in the tumor micro-environment remains unclear. In addition to identifying the ANS signaling pathways involved in tumor progression, recent reports suggest that the ANS could be a potential biomarker to predict tumor progression, and have identified new pharmacological strategies, such as the use of β-adrenergic blockers, to inhibit tumor progression and metastasis by targeting this system. These findings are reviewed here.
Export Options
About this article
Cite this article as:
Xu Zhifang, Shioda Seiji, Masahisa Jinushi, Kawakami Yutaka, Ohtaki Hirokazu, Lim Calista Huimin, Wang Shenjun, Zhao Xue, Liu Yangyang, Zhou Dan and Guo Yi*, Role of the Autonomic Nervous System in the Tumor Micro-Environment and its Therapeutic Potential, Current Pharmaceutical Design 2017; 23 (11) . https://dx.doi.org/10.2174/1381612822666161025152942
DOI https://dx.doi.org/10.2174/1381612822666161025152942 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Novel Perspectives on Nanotechnological and Biomedical Implications of Monotherapy or Combination Regimen of Lactoferrin
Current Pharmaceutical Design Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Recent Advances of p53-MDM2 Small Molecule Inhibitors (2011-Present)
Current Medicinal Chemistry Bioavailability Enhancement of Poorly Soluble Drugs: The Holy Grail in Pharma Industry
Current Pharmaceutical Design Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Targeting the EGF/HER Ligand-Receptor System in Cancer
Current Pharmaceutical Design Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Imaging Findings of Calcifying Nested Stromal-Epithelial Tumour of the Liver: A Case Report and Literature Review
Current Medical Imaging Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1<sup>®</sup> can Overcome Drug Resistance in Osteosarcoma
Current Cancer Drug Targets Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism The Toolbox of Designing Nanoparticles for Tumors
Mini-Reviews in Medicinal Chemistry Understanding the Multifaceted Role of Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2) and its Altered Behaviour in Human Diseases
Current Molecular Medicine Study of HIV Resistance Mutations Against Antiretrovirals using Bioinformatics Tools
Current HIV Research Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy